Search clinical trials for: BMS-986165

Total 1992 results

Duke University
Bristol-Myers Squibb

Completed

Phase II Dasatinib Study in Advanced Breast Cancer

Advanced Breast Cancer

United States
PPD

Unknown

Differences Between Women and Men Taking a Combination of Indinavir, Ritonavir, Enteric-Coated Didanosine, and Stavudine Who Previously Took Anti-HIV Drugs

HIV Infections

United States, Puerto Rico
Celgene

Recruiting

Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States, Australia, Spain, Canada, United Kingdom
Janssen Research & Development, LLC
Bristol-Myers Squibb

Completed

A Study of JNJ-70033093 in Healthy Participants

Healthy

Belgium
Bristol-Myers Squibb

Completed

Study to Evaluate KOS-1584 in Patients With Advanced or Metastatic Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

United States
Celgene

Not yet recruiting

A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment

Renal Impairment

United States
Bristol-Myers Squibb
Celgene

Completed

A Study to Compare the Relative Bioavailability of Two Iberdomide (CC-220) Formulations and to Assess The Effect Of Food on the Drug Levels of Iberdomide in Healthy Adult Participants

Healthy Volunteers

United States
Aegerion Pharmaceuticals, Inc.
FDA Office of Orphan Products Development

Completed

A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)

Homozygous Familial Hypercholesterolemia

United States, Canada, Italy, South Africa
Aegerion Pharmaceuticals, Inc.
University of Pennsylvania; Doris Duke Charitable Foundation

Completed

Safety, Tolerability and Efficacy of Microsomal Triglyceride Protein (MTP) Inhibitor

Homozygous Familial Hypercholesterolemia

United States
Bristol-Myers Squibb

Withdrawn

Ascending Multiple-Dose Study of BMS-817378 in Subjects With Advanced Cancers

Advanced Solid Tumors

Australia, Singapore
Bristol-Myers Squibb

Completed

MAD Refractory: Solid Tumor QD w/o Break

HER2 or EGFR Expressing Advanced Solid Malignancies

Spain, France
Bristol-Myers Squibb

Completed

Safety Study to Evaluate BMS-830216 in Healthy Subjects

Obesity

United States
Bristol-Myers Squibb

Completed

A Two-Part, Phase 1, Single-Dose Study of IL-31 mAb (Anti-Interleukin 31 Monoclonal Antibody); in Healthy Subjects and Adults With Atopic Dermatitis

Healthy Subjects and Atopic Dermatitis Subjects

United Kingdom
Bristol-Myers Squibb

Completed

A Study of BMS-582949 in Patients With Moderate to Severe Plaque Psoriasis

Psoriasis

Australia, Canada, Mexico
Bristol-Myers Squibb

Completed

A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male Subjects

Rheumatoid Arthritis

United States
Bristol-Myers Squibb

Recruiting

A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus

United States, Taiwan, Japan, United Kingdom, Brazil, Colombia, Poland, Puerto Rico, China, France, Chile, Australia, Mexico, Germany, Argentina, India, Spain, Romania, Ireland
R-Pharm

Completed

Study of Ixabepilone in Asian Subjects With Unresectable or Metastatic Gastric Cancer

Stomach Neoplasms

Korea, Republic of, Taiwan, Japan, Singapore, Hong Kong
Biogen

Completed

Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy (CN002-003)

Progressive Supranuclear Palsy

United States
Bristol-Myers Squibb

Completed

Safety, Pharmacokinetics and Pharmacodynamics Study to Evaluate BMS-830216 in Obese Subjects

Obesity

United States
Bristol-Myers Squibb

Terminated

A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease

Alzheimer's Disease

Sweden, United States, Canada, Denmark, France, Finland
National Center for AIDS/STD Control and Prevention...
BMS company

Completed

Unboosted Atazanavir as Initial ART Therapy in China

Antiretroviral Therapy

China
National Institutes of Health Clinical Center (CC)
Bristol-Myers Squibb; National Institute of Allergy and Infectious Diseases...

Completed

Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCV

HIV-HCV

United States
Janssen Research & Development, LLC
Bristol-Myers Squibb

Recruiting

A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)

Acute Coronary Syndrome

United States, Taiwan, Korea, Republic of, Italy, South Africa, Israel, Belgium, Argentina, Malaysia, Romania, Serbia, China, Australia, Netherlands, United Kingdom, Denmark, Czechia, Hungary, Japan, France, Canada, Bulgaria, Spain, T... and more
Aventyn, Inc.
University of California; BMS Hospital Trust; AT&T; Zephyr Technology

Completed

Evaluate Heart Failure Patients With Specially Designed Patient Adherence and Monitoring Software on Standard Mobile Devices (REMOTE-HF-1)

Cardiac Decompensation

United States, India, Sweden
Bristol-Myers Squibb

Withdrawn

A Study of Absorption, Metabolism, and Elimination CC-90010 in Participants With Advanced Solid Tumors

Advanced Solid Tumors

Spain
Bristol-Myers Squibb
Exelixis

Terminated

A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors

Metastatic Cancer | Advanced Solid Cancers

United States, Canada, France
Cancer Institute and Hospital, Chinese Academy...

Unknown

HFSRT With Concurrent TMZ for Large BMs

Chemotherapy | Brain Metastases | Radiotherapy

China
Bristol-Myers Squibb

Terminated

Safety and Pharmacology Study of BMS-866949

Major Depression

Sweden
Bristol-Myers Squibb

Completed

Assessment of Blood Glucose Changes in Healthy Volunteers After BMS-754807 Alone or BMS-754807 With Metformin (NHV)

Healthy Volunteers

Australia
Medical University of Silesia
Wojciech Wojakowski

Completed

New-DES vs BMS in SVG -1 Year Outcomes (BALTIC)

Coronary Artery Disease

Poland
Bristol-Myers Squibb

Completed

To Evaluate the Safety and Pharmacokinetics of BMS-986177 in Healthy Japanese Participants

Thrombosis

United States
M.D. Anderson Cancer Center

Active, not recruiting

BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers

Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Carcinoma in the Liver | Metastatic Carcinoma in the Lung | Metastatic Malignant Neoplasm in the Thoracic Cavity

United States
Bristol-Myers Squibb

Active, not recruiting

A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Rheumatoid Arthritis

Italy, United States, Germany, Argentina, Australia, Czechia, France, Japan, Mexico, Poland, Spain, Switzerland, Taiwan, United Kingdom
M.D. Anderson Cancer Center
Bristol-Myers Squibb; United States Department of Defense

Completed

Dasatinib in Resectable Malignant Pleural Mesothelioma

Malignant Pleural Mesothelioma

United States
Nasser Hanna, M.D.
Bristol-Myers Squibb; Hoosier Cancer Research Network

Terminated

Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor

Lung Cancer | Squamous Cell Lung Cancer | Adenocarcinoma of the Lung | Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

United States
The Lymphoma Academic Research Organisation
Lymphoma Study Association

Not yet recruiting

Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse

Refractory High Grade B-Cell Lymphoma | Diffuse Large B-cell Lymphoma Refractory | Refractory Transformed B-cell Non-Hodgkin Lymphoma | Refractory Primary Mediastinal Large B-Cell Lymphoma

France
Bristol-Myers Squibb

Recruiting

A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 in Participants With Relapsed or Refractory T-cell Lymphomas in Japan

Relapsed or Refractory T-cell Lymphomas

Japan
Janssen Research & Development, LLC

Completed

A Study of JNJ-70033093 (Milvexian) in Healthy Adult Participants

Healthy

United States
Bristol-Myers Squibb

Active, not recruiting

A Study to Evaluate the Efficacy, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy (MERCUTIO)

Cardiomyopathy, Hypertrophic

Italy, United States, Poland, Spain
ViiV Healthcare
GlaxoSmithKline

Completed

Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects With Hepatic Impairment Compared to Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
R-Pharm

Terminated

Phase 1 Trial of Oral Ixabepilone

Advanced Solid Tumors

United States
Bristol-Myers Squibb

Withdrawn

Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C

Hepatitis C Virus

United States
Bristol-Myers Squibb

Recruiting

Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) (AURORA-HFpEF)

Heart Failure

United States, Spain, Canada, Italy, Poland
Bristol-Myers Squibb

Recruiting

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) (SUCCESSOR-2)

Relapsed or Refractory Multiple Myeloma

United States, Austria, Denmark, Canada, Australia, China, Spain, Germany, United Kingdom, Hungary, Taiwan, Israel, Japan, India, Norway, Brazil, Italy, Greece, Korea, Republic of, Colombia, Singapore, Netherlands, Argentina, Hong Kong, Romani... and more
Bristol-Myers Squibb

Completed

A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants

Healthy Volunteers

United States
University of California, Davis
National Cancer Institute (NCI)

Completed

Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer

Lung Cancer | Unspecified Adult Solid Tumor, Protocol Specific

United States
Bristol-Myers Squibb
Solvay Pharmaceuticals

Terminated

Multiple-dose Study to Evaluate the Efficacy, Safety and Pharmacokinetics of BMS-646256 in Obese Subjects

Obesity

United States
Allyx Therapeutics
Yale University; National Institute on Aging (NIA)

Recruiting

A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease

Alzheimer's Disease

United States
Bristol-Myers Squibb

Completed

Multiple Dose Japanese Bridging Study

Alzheimer Disease

United States
Bristol-Myers Squibb

Completed

A Phase I Study of BMS-641988 in Japanese Patients With Castration Resistant Prostate Cancer

Prostate Cancer

Japan

Search clinical trials for: BMS-986165

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Romania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations